S&P may cut Fresenius

Standard & Poor's said it placed the BB+ unsecured debt ratings and 2 recovery ratings on Fresenius SE's (BB corporate credit rating) on CreditWatch with negative implications as a result of the APP Pharmaceuticals Inc. acquisition.

The watch reflects expectation that the company will raise a significant amount of additional debt to finance the acquisition of APP Pharmaceuticals Inc., including a material portion of secured debt ranking ahead of the existing unsecured facilities, according to the agency.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.